Hybrid Event | Lunch and Learn with CASTL
Join D2R and 聽for this hybrid Lunch and Learn about biomanufacturing and RNA therapeutics
In this presentation, D2R and CASTL will connect the world of research with industrial applications! This Lunch and Learn will provide a practical way introduce participants to how mRNA-LNP based biotherapeutics are manufactured, and showcase opportunities and career pathways in the biomanufacturing sector.聽
About the Speaker
Sven Ansorge聽
Sven has more than 15 years of experience in biopharmaceutical industry and R&D. He holds a PhD in Chemical Engineering from Polytechnique de Montr茅al and has led teams and projects within academic and industrial/GMP manufacturing environments. He is specialized in bioprocessing for the production of viral vectors, vaccines, recombinant proteins and cell therapy products.His experience spans from small biotech (Enobia/Alexion, ExCellThera) to large pharma (GSK, Belgium) and from R&D/process development to commercial GMP manufacturing. Since 2022, he works at the Canadian Alliance for Skills and Training in Life Sciences (CASTL). CASTL provides world-class technical skills development and training in life sciences specializing in biopharmaceutical manufacturing. It is a unique partnership between academia, industry, and government to address the future skills needs of the fast-growing bioscience sector. As Director of Technical Training, Sven currently oversees technical training that CASTL provides through its training facilities in Charlottetown (PEI), Montreal (QC) and Richmond (BC). Prior to joining CASTL, he led the manufacturing and process development activities at ExCellThera (2019-2022), a clinical stage cell therapy company and contributed to developing a cell therapy product towards commercial approval. From 2014-2019, he was at the National Research Council Canada (NRC) where he built and managed a team focusing on scaling-up cell culture-based suspension processes. This included process development and technology transfer of upstream bioprocesses using multiple cell line platforms. One of the focus areas was the development of perfusion-based lentiviral vector production processes, which Sven started to work on in 2006 as a PhD student under Amine Kamen鈥檚 supervision. Together with collaborators and colleagues, he has published more than 20 peer-reviewed manuscripts and has presented at multiple international conferences. Since 2019, he is an Adjunct Professor in the Department of Bioengineering at 涩里番.
Register
Be part of this exciting learning opportunity with industry!
For those attending in-person, there will be a networking session with light refreshments following the presentation.聽Space is limited!聽
Confirmation emails will be provided to registered participants a few days before the event.
